Biomarkers associated with progression of infantile hemangioma: Exploratory study
The Journal of Dermatology · 2025
DOI: 10.1111/1346-8138.17639 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Ken Miyazaki und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Cytokines, Skin Neoplasms, Hemangioma. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Maruho Co., Ltd., Maruho.
Abstract (Originalsprache)
To identify patients with infantile hemangioma (IH) in need of early‐stage treatment in this multicenter, prospective, observational study, we investigated the potential of plasma cytokines as a clinically useful marker. Plasma samples were collected at three time points from 41 patients with infantile hemangioma: baseline (days 14–60 after delivery), visit 1 (days 61–150, the proliferative phase), and visit 2 (days 151–395, the involuting phase). With a twofold or more increase in tumor volume during the baseline–visit 1 period regarded as progression, progression was seen in 15 cases (36.6%). In the first step, cytokine arrays were performed using plasma samples in five progressive and five non‐progressive cases. Plasma levels of six cytokines at baseline were selected for a prediction marker of change in tumor volume during baseline–visit 1. Validation enzyme‐linked immunosorbent assay indicated that the baseline growth differentiation factor 1 (GDF1) concentration tended to correlate with the proliferation ratio of total lesions or target lesion during baseline–visit 1, although without statistical significance. However, the plasma GDF1 concentrations were significantly lower in patients with a fourfold or more increase in total volume ( p = 0.013). Furthermore, changes in plasma interleukin (IL)‐7Rα levels showed a statistically significant inverse correlation between volume change of the target lesion during baseline–visit 1 ( p = 0.0069). Our results suggest that plasma GDF1 measurement after birth is a useful marker for progression of IH. Additionally, the downregulation of IL‐7Rα that begins several months after birth may also contribute to tumor growth. (UMIN‐CTR: UMIN000038574).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Wakayama Medical University, Wakayama, Japan.
- Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
- Innovative and Clinical Research Promotion Center, Gifu University Hospital, Gifu, Japan.
- Department of Pediatrics, Wakayama Medical University, Wakayama, Japan.
- Medical Affairs Department, Maruho Co., Ltd., Osaka, Japan.
ORCID-Profile: Ken Miyazaki, Kayo Kunimoto, Minako Tanaka, Masatoshi Jinnin
Förderung
- Maruho Co., Ltd.
- Maruho
Zitieren
APA
Miyazaki, K., Kunimoto, K., Yasue, S., Endo, S., Nozawa, A., Ozeki, M., Ishihara, T., Tanaka, M., Kakimoto, N., Suenaga, T., Tokuhara, D., Ohnishi, H., Inose, Y., & Jinnin, M. (2025). Biomarkers associated with progression of infantile hemangioma: Exploratory study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17639
Vancouver
Miyazaki K, Kunimoto K, Yasue S, Endo S, Nozawa A, Ozeki M, et al. Biomarkers associated with progression of infantile hemangioma: Exploratory study. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17639
BibTeX
@article{Miyazaki2025,
author = {Miyazaki, Ken and Kunimoto, Kayo and Yasue, Shiho and Endo, Saori and Nozawa, Akifumi and Ozeki, Michio and Ishihara, Takuma and Tanaka, Minako and Kakimoto, Nobuyuki and Suenaga, Tomohiro and Tokuhara, Daisuke and Ohnishi, Hidenori and Inose, Yuri and Jinnin, Masatoshi},
title = {Biomarkers associated with progression of infantile hemangioma: Exploratory study},
journal = {The Journal of Dermatology},
year = {2025},
doi = {10.1111/1346-8138.17639}
}
EUVIMED